Ovarian reserve after chemotherapy in breast cancer: A systematic review and meta-analysis

Alessia Romito, Luigi Michele Antonio Romito, Sonia Bove, Ilaria Romito, Drieda Zace, Ivano Raimondo, Simona Maria Fragomeni, Pierluigi Maria Rinaldi, Domenico Pagliara, Antonella Lai, Alessandro Lai, Fabio Marazzi, Claudia Marchetti, Ida Paris, Gianluca Franceschini, Riccardo Masetti, Giovanni Scambia, Alessandra Fabi, Giorgia Garganese

Risultato della ricerca: Contributo in rivistaArticolo in rivista


Background: Worldwide, breast cancer (BC) is the most common malignancy in the female population. In recent years, its diagnosis in young women has increased, together with a growing desire to become pregnant later in life. Although there is evidence about the detrimental effect of chemotherapy (CT) on the menses cycle, a practical tool to measure ovarian reserve is still missing. Recently, anti-Mullerian hormone (AMH) has been considered a good surrogate for ovarian reserve. The main objective of this paper is to evaluate the effect of CT on AMH value. Methods: A systematic review and meta-analysis were conducted on the PubMed and Scopus electronic databases on articles retrieved from inception until February 2021. Trials evaluating ovarian reserves before and after CT in BC were included. We excluded case reports, case-series with fewer than ten patients, reviews (narrative or systematic), communications and perspectives. Studies in languages other than English or with polycystic ovarian syndrome (PCOS) patients were also excluded. AMH reduction was the main endpoint. Egger’s and Begg’s tests were used to assess the risk of publication bias. Results: Eighteen trials were included from the 833 examined. A statistically significant decline in serum AMH concentration was found after CT, persisting even after years, with an overall reduction of -1.97 (95% CI: -3.12, -0.82). No significant differences in ovarian reserve loss were found in the BRCA1/2 mutation carriers compared to wild-type patients. Conclusions: Although this study has some limitations, including publication bias, failure to stratify the results by some important factors and low to medium quality of the studies included, this metanalysis demonstrates that the level of AMH markedly falls after CT in BC patients, corresponding to a reduction in ovarian reserve. These findings should be routinely discussed during oncofertility counseling and used to guide fertility preservation choices in young women before starting treatment.
Lingua originaleEnglish
pagine (da-a)1-14
Numero di pagine14
RivistaJournal of Personalized Medicine
Stato di pubblicazionePubblicato - 2021


  • AMH
  • Breast cancer
  • Chemotherapy
  • Ovarian reserve
  • Pregnancy desire


Entra nei temi di ricerca di 'Ovarian reserve after chemotherapy in breast cancer: A systematic review and meta-analysis'. Insieme formano una fingerprint unica.

Cita questo